Podcast
Questions and Answers
Which of the following is the most effective for prophylaxis of gout flares during the initiation of urate-lowering therapy?
Which of the following is the most effective for prophylaxis of gout flares during the initiation of urate-lowering therapy?
- Combination of naproxen and colchicine
- Placebo
- Colchicine 0.5 - 1.0 mg/day
- Naproxen (correct)
What percentage of subjects randomized to colchicine completed 8 weeks without a gout flare in the randomized controlled trial comparing naproxen and colchicine?
What percentage of subjects randomized to colchicine completed 8 weeks without a gout flare in the randomized controlled trial comparing naproxen and colchicine?
- 21% (correct)
- 50%
- 25%
- 36%
What was the primary finding of the double-blind randomized controlled trial that evaluated colchicine for gout flare prevention during the initiation of allopurinol?
What was the primary finding of the double-blind randomized controlled trial that evaluated colchicine for gout flare prevention during the initiation of allopurinol?
- Colchicine was more effective than placebo, with 25% of subjects in the colchicine group having a gout flare over 16 weeks. (correct)
- Colchicine was less effective than placebo, with 75% of subjects in the colchicine group having a gout flare over 16 weeks.
- There was no difference in efficacy between colchicine and placebo for preventing gout flares.
- The trial was stopped early due to safety concerns with colchicine.
What is the recommended dose range for colchicine used in published studies for prophylaxis of gout flares during the initiation of urate-lowering therapy?
What is the recommended dose range for colchicine used in published studies for prophylaxis of gout flares during the initiation of urate-lowering therapy?
Which of the following is a potential concern with the use of colchicine for prophylaxis of gout flares?
Which of the following is a potential concern with the use of colchicine for prophylaxis of gout flares?
What is the optimal duration of prophylaxis with NSAIDs or colchicine during the initiation of urate-lowering therapy?
What is the optimal duration of prophylaxis with NSAIDs or colchicine during the initiation of urate-lowering therapy?
Which of the following is NOT a reason for using prophylactic therapy during the initiation of urate-lowering therapy (ULT) for gout?
Which of the following is NOT a reason for using prophylactic therapy during the initiation of urate-lowering therapy (ULT) for gout?
Which of the following is the recommended duration for providing prophylactic therapy when initiating ULT for gout?
Which of the following is the recommended duration for providing prophylactic therapy when initiating ULT for gout?
What is the recommended lower limit of the colchicine dosing range for prophylaxis of acute gout in patients without a history of chronic liver disease or dialysis?
What is the recommended lower limit of the colchicine dosing range for prophylaxis of acute gout in patients without a history of chronic liver disease or dialysis?
Which of the following statements about the use of NSAIDs for gout prophylaxis is correct?
Which of the following statements about the use of NSAIDs for gout prophylaxis is correct?
What is the main reason why dose adjustment of urate-lowering therapy (ULT) is crucial in managing gout treatment?
What is the main reason why dose adjustment of urate-lowering therapy (ULT) is crucial in managing gout treatment?
Which of the following is a potential disadvantage of using corticosteroids for acute gout flares?
Which of the following is a potential disadvantage of using corticosteroids for acute gout flares?
Which of the following is NOT a potential reason why a gout flare may occur during the initiation of urate-lowering therapy (ULT)?
Which of the following is NOT a potential reason why a gout flare may occur during the initiation of urate-lowering therapy (ULT)?
What is the recommended approach for preventing recurrent gout flares during urate-lowering therapy (ULT)?
What is the recommended approach for preventing recurrent gout flares during urate-lowering therapy (ULT)?
What is the rationale behind the recommendation to titrate the dose of allopurinol gradually when initiating urate-lowering therapy (ULT) for gout?
What is the rationale behind the recommendation to titrate the dose of allopurinol gradually when initiating urate-lowering therapy (ULT) for gout?
Flashcards are hidden until you start studying
